Zevra Therapeutics, Inc. (ZVRA)

Market Cap	405.86M
Revenue (ttm)	62.02M
Net Income (ttm)	-3.91M
Shares Out	56.14M
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	61.53
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,319,532
Open	7.73
Previous Close	7.75
Day's Range	7.22 - 7.75
52-Week Range	6.19 - 13.16
Beta	1.56
Analysts	Strong Buy
Price Target	22.67 (+213.56%)
Earnings Date	Nov 11, 2025

About ZVRA

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical tria...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 16, 2015
• Employees: 59
• Stock Exchange: NASDAQ
• Ticker Symbol: ZVRA
• Website: https://zevra.com

Financial Performance

In 2024, Zevra Therapeutics's revenue was $23.61 million, a decrease of -14.02% compared to the previous year's $27.46 million. Losses were -$105.51 million, 129.1% more than in 2023.

Analyst Summary

According to 10 analysts, the average rating for ZVRA stock is "Strong Buy." The 12-month stock price target is $22.67, which is an increase of 213.56% from the latest price.

Price Target

$22.67

(213.56% upside)

Analyst Consensus: Strong Buy